425: Rafael Holdings to Merge with Cyclo Therapeutics, Focusing on Niemann-Pick Disease Type C1 Treatment

Rafael Holdings and Cyclo Therapeutics have entered into a definitive merger agreement to focus on developing Trappsol Cyclo for treating Niemann-Pick Disease Type C1.

Summary

• Rafael Holdings and Cyclo Therapeutics have agreed to merge, concentrating on the development of Trappsol Cyclo for Niemann-Pick Disease Type C1.
• Rafael Holdings will issue Class B common stock to Cyclo Therapeutics shareholders, valuing Cyclo shares at $0.95 each.
• The valuation of Rafael Holdings is based on its cash, marketable securities, and certain other investments, less current liabilities.
• The cash value will consider Rafael's funding of Cyclo's operations through convertible notes until the merger's closing.
• Following the merger, Rafael Holdings plans to fund the TransportNPC clinical trial up to its 48-week interim analysis.
• The merger, approved by both boards, is expected to close in late 2024, pending shareholder approvals, SEC effectiveness of the registration statement, and other standard conditions.
• Cyclo Therapeutics completed enrollment in its pivotal TransportNPC Phase 3 clinical study in May 2024, with 48-week interim analysis results expected in mid-2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The merger is presented as a strategic move to advance a promising treatment, but the success depends on future clinical trial results and regulatory approvals. There are also inherent risks associated with the pharmaceutical industry and the small market for rare disease treatments.

Positives

• The merger will combine resources to focus on a promising treatment for a rare disease.
• Rafael Holdings' financial strength will support the continued development of Trappsol Cyclo.
• The TransportNPC clinical trial is fully enrolled, indicating progress in the drug's development.
• The merger aligns with Rafael Holdings' strategy to invest in clinical-stage assets with high unmet medical needs.

Risks

• The merger is subject to shareholder and regulatory approvals, and may not close in the anticipated timeframe or at all.
• The success of Trappsol Cyclo is dependent on the outcome of clinical trials, which are subject to inherent risks and uncertainties.
• The market for Niemann-Pick Disease Type C1 treatments is small, which may limit the commercial potential of Trappsol Cyclo.

Future Outlook

Rafael Holdings intends to focus its efforts on making Trappsol Cyclo its lead clinical program upon closing of the merger transaction with Cyclo Therapeutics.

Management Comments

• Bill Conkling, President and CEO of Rafael Holdings, stated that the merger is a major step forward in their strategy to invest in, develop, and commercialize clinical-stage assets in areas of high unmet medical need.
• N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, believes that the strength of Rafael's balance sheet and its strong management team will solidify their commitment to deliver the results of the TransportNPC trial.

Industry Context

This merger reflects a trend in the pharmaceutical industry where larger companies acquire smaller, specialized firms to gain access to promising drug candidates and expertise in specific therapeutic areas. It also highlights the growing interest in treatments for rare diseases, which often qualify for orphan drug status and offer market exclusivity.

Comparison to Industry Standards

• The valuation of Cyclo Therapeutics at $0.95 per share will be closely watched by investors, as it will be compared to other recent acquisitions in the biotechnology space, particularly those involving companies focused on rare diseases.
• The funding commitment from Rafael Holdings to support the TransportNPC clinical trial will be compared to industry benchmarks for clinical trial funding, considering the stage of development and the target indication.
• The timeline for closing the merger (late 2024) will be assessed against typical timelines for similar transactions, taking into account regulatory and shareholder approval processes.
• Comparible companies include BioMarin Pharmaceutical, Sarepta Therapeutics, and Vertex Pharmaceuticals, which are all focused on rare diseases.

Stakeholder Impact

• Shareholders of Cyclo Therapeutics will receive Rafael Holdings stock, potentially benefiting from the combined company's future success.
• Patients with Niemann-Pick Disease Type C1 may benefit from the accelerated development of Trappsol Cyclo.
• Employees of both companies may experience changes in their roles and responsibilities as a result of the merger.

Next Steps

• Obtain shareholder approvals from both Rafael Holdings and Cyclo Therapeutics.
• Secure effectiveness of the registration statement from the SEC.
• Fulfill other customary closing conditions.
• Rafael Holdings to fund Cyclo's TransportNPC clinical trial to its 48-week interim analysis.
• Complete the merger, expected in late 2024.

Key Dates